Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Drug Costs Can’t Be Curbed with Uniform Pricing of Gx, LLPs: Teva Takeda CEO
April 24, 2017
- With Upsher-Smith Deal Inked, Sawai Looks to Make US Market Its Second Biz Pillar
April 24, 2017
- Janssen’s Sirukumab Exhibits Significant Improvements in Primary Endpoints in Japanese PIII Studies
April 24, 2017
- Benralizumab Demonstrates Favorable Results in Subgroup Analysis of Japanese Bronchial Asthma Patients: AZ
April 24, 2017
- Janssen Files Japan NDA for Psoriasis Med Guselkumab
April 21, 2017
- Lecture Materials Prepared from Information Taken from Medical Charts: Bayer’s Xarelto Issue Whistleblower
April 21, 2017
- Sawai to Buy US Generic Maker Upsher-Smith
April 20, 2017
- Takeda’s “Health Innovation Park” Hoped to Bring Together Various Researchers, Other Companies Also Welcomed
April 20, 2017
- Eisai to Continue “Price Zero” Drug Supply to Stamp Out Lymphatic Filariasis
April 20, 2017
- Burosumab Hits Primary Endpoint in PIII for Adult X-Linked Hypophosphatemia: Kyowa Kirin
April 20, 2017
- “Headquarters Involvement Clear” in Access to Patient Medical Charts by Bayer Sales Reps: Attorney for Whistleblower
April 20, 2017
- Xarelto Issue Morally Questionable, but Does Not Constitute Misleading Ads Banned under Law: MHLW Officials
April 20, 2017
- Japan Vaccine Files New Shingles Vaccine: GSK
April 19, 2017
- Biogen’s Sugino to Lead Amgen Astellas; R&D Head Torii Named Successor
April 19, 2017
- AZ Boosting Field Force Specialization with Move to Business Units: Japan Chief
April 19, 2017
- Fujifilm Completes Bio Production Facility in US, Aiming to Initiate Operations in Early 2018
April 19, 2017
- Ex-Takeda Exec Noguchi Becomes President of Celgene Japan
April 18, 2017
- Boehringer Japan Logs 14 Consecutive Years of Growth in Ethical Drug Sales
April 18, 2017
- Celgene Submits Biz Improvement Plan over Side Effect Reporting Violation
April 18, 2017
- Japan Hemophilia Market Likely to Expand to Nearly 70 Billion Yen in 2024: Fuji Keizai
April 17, 2017
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…